InflaRx N.V. (IFRX) Stock: A Biotechnology Stock That’s Falling


InflaRx N.V. (IFRX) is falling in the market in today’s trading session. The stock, one that is focused on the biotech space, is presently trading at $2.69 after a move down of -5.28% so far in today’s session. As it relates to biotechnology companies, there are several aspects that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines relating to IFRX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-14-19 04:05PM InflaRx Reports Second Quarter 2019 Financial & Operating Results
Jul-19-19 12:43PM Do Insiders Own Shares In InflaRx N.V. (NASDAQ:IFRX)?
Jul-18-19 04:01PM InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
09:55AM InflaRx Enters Oversold Territory
Jun-29-19 11:31PM Hedge Funds Have Never Been This Bullish On InflaRx N.V. (IFRX)

However, any time investors are making a decision to invest, investors should focus on far more than just news, this is especially the case in the speculative biotech sector. Here’s what’s going on with InflaRx N.V..

Recent Movement Out of IFRX

Although a move toward the top in a single session, like the fall that we’re seeing from InflaRx N.V. may lead to fear in some investors, a single session decline by itself should not be the basis of a decision to, or not to, buy a company’s stock. It’s generally a good idea to look into trends just a single session. When it comes to IFRX, here are the returns on investment that we have seen:

  • Weekly – In the last five trading sessions, IFRX has generated a price change that amounts to 2.28%.
  • Past Month – The ROI from InflaRx N.V. over the last 30 days has been -5.94%.
  • Past Quarter – Over the past three months, the company has produced a return that comes to -92.34%
  • Past Six Months – Over the last six months, investors have seen a change of -91.80% from the company.
  • This Year So Far – Since the the first trading session of this year IFRX has generated a ROI of -92.60%.
  • Annually – Lastly, in the last year, we’ve seen movement in the amount of -91.21% out of IFRX. In this period, the stock has sold at a high price of -94.93% and a low of 9.80%.

Ratios That Are Notable

Digging into various ratios having to do with a company can give prospective traders a view of just how dangerous and/or potentially profitable a an investment option may be. Below are some of the key ratios to consider when looking at IFRX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it shows that more investors have a belief that the stock is going to fall. Throughout the sector, biotech stocks can carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, with regard to InflaRx N.V., the stock’s short ratio is 0.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to pay for its debts when they come due with only current assets or quick assets. In the biotechnology industry, many companies are heavily reliant on the continuation of investor support, these ratios can seem upsetting. Nonetheless, several good picks in the biotechnology sector come with good current and quick ratios. When it comes to IFRX, the quick and current ratios add up to 18.10 and 18.10 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this particular case, that ratio works out to 6.24.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to think about. In terms of IFRX, the cash to share value is 2.07.

How Analysts Feel About InflaRx N.V.

While it’s never a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to use their opinions when validating your own opinions before making an investment decision in the biotech space. Here are the recent moves that we have seen from analysts as it relates to IFRX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-05-19 Downgrade SunTrust Buy → Hold $55 → $5
Jun-05-19 Downgrade Robert W. Baird Outperform → Neutral $58 → $6
Jun-05-19 Downgrade JP Morgan Overweight → Underweight $67 → $9
Jun-05-19 Downgrade Guggenheim Buy → Neutral $65 → $6
Jun-05-19 Downgrade BMO Capital Markets Outperform → Market Perform $5

Moves From Big Money Players

An interesting fact that I’ve come to understand so far in my brief time as an intelligence is that smart investors tend to follow the moves made by big money investors. In other words, investors that want to keep the risk down will watch moves made by institutions and those on the inside. So, what does the big money picture look like in regard to IFRX? Here’s the information:

  • Institutional Investors – Currently, institutional investors own 19.90% of InflaRx N.V.. Nonetheless, it is important to consider that the ownership held by institutions has moved in the amount of -68.49% over the last 3 months.
  • Insider Moves – When it comes to insiders, members of the management team and others close to IFRX currently own 0 of the company. Insider ownership of the company has moved 0 throughout the last 3 months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 25.29M shares of InflaRx N.V. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IFRX has a float of 15.95M.

I also find it important to follow the short float. Think about it, when a high portion of the float available for trading is sold short, the overall opinion in the market is that the equity is going to lose value. When it comes to IFRX, the percentage of the float that is currently being sold short sits at 0. In general, concerning short percent of the float would be considered to be anything over 40%. Through my work, I’ve seen that any short ratio over 26% is likely a a play that could prove to be very risky.

Financial Performance

What have ween seen from IFRX in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, analysts have expectations that the company will generate earnings per diluted share that totals up to be -2.15, with -0.56 to be reported in the earnings report for the current quarter. Although this is not earnings driven, since we’re talking on the topic of analysts, the stock is currently graded as a 0 when rated on a scale from 1 to 5 where 1 is the worst average Wall Street analyst rating and 5 is the best rating.
  • 5-Year Sales – In the past 5 years, InflaRx N.V. has announced a change in sales that comes to a total of 0. EPS in the past 5 years have experienced movement in the amount of 0.
  • Quarter Over Quarter – In terms of quarter over quarter data, or Q/Q data as it is often referred to as in today’s society, the company has created a change in earnings that amounts to 8.30%. IFRX has also experienced a change in regard to sales that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was made by a human and human beings actually play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here